103 related articles for article (PubMed ID: 9630340)
1. Further insights into the anti-aggregating activity of NMDA in human platelets.
Franconi F; Miceli M; Alberti L; Seghieri G; De Montis MG; Tagliamonte A
Br J Pharmacol; 1998 May; 124(1):35-40. PubMed ID: 9630340
[TBL] [Abstract][Full Text] [Related]
2. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
3. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l-arginine: effects of arterial hypertension.
Brunini T; Moss M; Siqueira M; Meirelles L; Rozentul A; Mann G; Ellory J; Soares de Moura R; Mendes-Ribeiro A
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):738-40. PubMed ID: 15554917
[TBL] [Abstract][Full Text] [Related]
6. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
7. Virgin olive oil polyphenol hydroxytyrosol acetate inhibits in vitro platelet aggregation in human whole blood: comparison with hydroxytyrosol and acetylsalicylic acid.
Correa JA; López-Villodres JA; Asensi R; Espartero JL; Rodríguez-Gutiérez G; De La Cruz JP
Br J Nutr; 2009 Apr; 101(8):1157-64. PubMed ID: 18775097
[TBL] [Abstract][Full Text] [Related]
8. Effects of magnesium lithospermate B on aggregation and 5-HT release in rabbit washed platelets.
Wang W; Wang YP; Sun WK; Xu YM; Xuan LJ
Acta Pharmacol Sin; 2000 Sep; 21(9):859-63. PubMed ID: 11501172
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
[TBL] [Abstract][Full Text] [Related]
10. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate-evoked release of cyclo-oxygenase products in rabbit hippocampus: an in vivo microdialysis study.
Lazarewicz JW; Salińska E
J Neurosci Res; 1995 Apr; 40(5):660-6. PubMed ID: 7602616
[TBL] [Abstract][Full Text] [Related]
12. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Bode-Böger SM; Böger RH; Galland A; Frölich JC
Naunyn Schmiedebergs Arch Pharmacol; 1998 Feb; 357(2):143-50. PubMed ID: 9521487
[TBL] [Abstract][Full Text] [Related]
14. Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.
González-Correa JA; Arrebola MM; Guerrero A; Muñoz-Marín J; Ruiz-Villafranca D; Sánchez de La Cuesta F; De La Cruz JP
Platelets; 2005; 16(3-4):171-9. PubMed ID: 16011961
[TBL] [Abstract][Full Text] [Related]
15. Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers.
Albert J; Wall n NH; Li N; Frostell C; Hjemdahl P
Clin Sci (Lond); 1999 Sep; 97(3):345-53. PubMed ID: 10464060
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
[TBL] [Abstract][Full Text] [Related]
17. Studies on the importance of the proposed release of nitric oxide from platelets.
Mollace V; Salvemini D; Vane J
Thromb Res; 1991 Dec; 64(5):533-42. PubMed ID: 1725563
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets.
Chen L; Salafranca MN; Mehta JL
Am J Physiol; 1997 Oct; 273(4):H1854-9. PubMed ID: 9362253
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets.
Sheu JR; Hsiao G; Chou PH; Shen MY; Chou DS
J Agric Food Chem; 2004 Jul; 52(14):4414-8. PubMed ID: 15237945
[TBL] [Abstract][Full Text] [Related]
20. NMDA receptors play an anti-aggregating role in human platelets.
Franconi F; Miceli M; De Montis MG; Crisafi EL; Bennardini F; Tagliamonte A
Thromb Haemost; 1996 Jul; 76(1):84-7. PubMed ID: 8819257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
